Tate & Lyle Revenue Rises 1% on Volume Gains
The sweetener maker's first-half revenue grew to £1bn despite price cuts, while EBITDA fell 8% to £197m.
Updated on Nov. 5, 2026 in Corporate Finance
Tate & Lyle reported first-half revenue growth of 1% to £1bn, with volumes rising 3% after the group cut prices. EBITDA fell 8% to £197m, and shareholders approved its acquisition by US rival Ingredion on 28 July 2026.
Why it matters
The results show a company trading volume for margin while it moves toward a combination with Ingredion. Rising costs linked to the Iran war are expected to be passed through, adding pressure on the group's profitability.
Tate & Lyle's first-half revenue rose 1% to £1bn and volumes grew 3%, while EBITDA fell 8% to £197m. The group is partway through a $200m (£148m) five-year productivity programme, with $27m of savings achieved in the half to 30 September 2026.
The players
Tate & Lyle
A global specialty food and beverage ingredients company known for sweeteners and texturants used by manufacturers worldwide.
Ingredion
A US-based ingredients company that agreed to acquire Tate & Lyle, with shareholders of the British firm approving the deal on 28 July 2026.
The details
Revenue growth was led by a 3% increase in volumes following price cuts made in the first half. The company also recorded a one-off $10m impact from consolidating its bio-gums manufacturing, and it maintained guidance for modest full-year revenue growth with EBITDA expected to be broadly flat.
Timeline
28 July 2026: Shareholders approved the acquisition by Ingredion.
30 September 2026: End of the half-year period in which $27m of savings were achieved.
5 November 2026: Half-year results published.
Market Landscape
The planned acquisition by Ingredion reflects continued consolidation among global ingredient makers seeking scale in sweeteners and texturants. Tate & Lyle's decision to cut prices to lift volumes shows how competitive pressure in this sector is shaping near-term margins.
Shareholders have approved the Ingredion acquisition, so the deal's completion will determine how Tate & Lyle stock is valued going forward. Investors tracking the company should weigh the 8% EBITDA decline against guidance for flat full-year EBITDA.
The takeaway
Tate & Lyle is buying growth with lower prices while cutting costs through its productivity programme. Watch for how the Ingredion deal and rising input costs shape margins in the coming half-year reports.
Further reading
Explore more company earnings and deal coverage in the Corporate Finance section.
